Doubling Down: Merck Serono Inks Second Oncology Deal With Chinese Biotech BeiGene
This article was originally published in PharmAsia News
Executive Summary
German drug maker Merck Serono inked its second global licensing, co-development and commercialization deal this year with Chinese biotech BeiGene. During a signing ceremony in Beijing, execs from both companies talked about their development strategy.
You may also be interested in...
Tandem Approval Brings GSK’s Tafinlar And Mekinist To A Market Ready To Test Combinations
Glaxo’s BRAF inhibitor dabrafenib and MEK inhibitor trametinib were approved as single agents for advanced melanoma, but the real promise lies in combination therapy for better efficacy and safety. Labeling for trametinib notes it is not indicated in patients who have already received BRAF therapy.
Merck Serono Opens Bioanalysis Center In Beijing To Support Clinical Trials In Asia; Plans To Double Staff
SHANGHAI - Merck KGaA's biopharmaceutical arm Merck Serono SA opened Aug. 31 a new R&D laboratory in Beijing to establish bioanalysis capability that will support clinical trials in Asia. The site is on Chinese contract research organization Pharmaron's new campus in the Beijing Economic and Technological Development Area
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.